A proof-of-concept system reported RuPHOTACs, a ruthenium-based, red-light-activated approach to control PROTAC protein degradation in time and space. The system keeps the PROTAC inactive until exposed to specific light conditions, aiming to reduce off-target effects in healthy tissues. The work leverages the PROTAC mechanism—binding a target protein and recruiting the ubiquitin machinery—while addressing selectivity through activation control. By using a ruthenium photochemistry designed to respond to low-energy red light, the authors propose a route toward minimizing collateral degradation. The report is positioned as an early demonstration, but it directly targets a known translational barrier for degrader therapeutics: controlling where and when protein destruction occurs.